Non-replicating mRNA Vaccine Platform
In addition to Self-amplifying RNA vaccine, Creative Biolabs also provides development services for Non-replicating mRNA vaccines. Equipped with a team of professional scientists, we are capable of providing specialized support in the design, production and evaluation of mRNA vaccines to bring your mRNA therapeutics for conventional protein replacement therapy closer to clinical realization. We can accommodate the specific attributes of your project and provide flexible, integrated solutions.
Self-amplifying mRNA (SAM) vaccines do not use modified nucleosides, while non-replicating mRNA vaccines can be prepared with or without the addition of various modified nucleosides. Directly injected non-replicating mRNA vaccine is an attractive form of vaccine due to its simple and economical application, especially in resource-constrained environments.
Table 1. Comparation between Self-amplifying mRNA and Non-replicating mRNA.
|
Self-amplifying mRNA (SAM) | Non-replicating mRNA |
| Potency | The auto-replicative ability of SAM enables the production of high levels of vaccine antigen in host cells. The duration of protein expression from the SAM molecule is enhanced. | High levels of protein translation require very efficient delivery systems and relatively high doses. |
| Safety | Similar to non-replicating unmodified and non-purified mRNA, SAM can induce high levels of inflammation. Moreover, SAM transfected cells may die due to a continuous replication cycle. A lower effective dose can be used for SAM than non-replicating mRNA. | Potent type I interferon response elicited by non-purified and unmodified mRNA can induce severe inflammation. Potential toxic effects may result from the use of non-natural nucleotides and various delivery system components. |
| Immunity against the Vector | No anti-vector effects have been observed yet, but potential interactions between the encoded non-structural proteins and host factors require further investigation. | No theoretical risk of anti-vector immunity with non-viral delivery systems. |
Considerations for Effectiveness of Directly Injected mRNA Vaccines
- The level of antigen expression in APCs is influenced by carrier efficiency, presence of PAMPs in the form of dsRNA or unmodified nucleosides and the level of optimization of the RNA sequence.
- Dendritic cell (DC) maturation and migration to secondary lymphoid tissue is increased by PAMPs.
- The area of vaccines activating powerful T-follicular helper cells and germinal center B cell responses is still poorly understood.
Fig.2 Considerations for effectiveness of a directly injected mRNA vaccine. (Pardi N. 2018)
With the commitment of being your best vaccine development partner, Creative Biolabs has established the utmost efficient integrated solutions to innovate and accelerate your vaccine development for various types of diseases. If you are interested in our services, please contact us to get more information or directly send us an online inquiry.
References
- Scorza FB and Pardi N. New Kids on the Block: RNA-Based Influenza Virus Vaccines. Vaccines (Basel). 2018, 6(2).
- Pardi N, et al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018, 17(4):261-279.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
